Adverse reactions and pathogen safety of intravenous immunoglobulin

Current Drug Safety

Volumn 2, Issue 1, 2007, Pages 9-18

  Carbone, Javier ^a  

^a HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

Author keywords

Adverse reactions; Intravenous immunoglobulin; Pathogen safety; Transfusion; Transmission; Virus

Indexed keywords

ACETYLSALICYLIC ACID; ADRENALIN; ALCOHOL; ANTIBIOTIC AGENT; ANTIMIGRAINE AGENT; DETERGENT; DIPHENHYDRAMINE; GLUCOSE; GLYCINE; HYDROCORTISONE; IBUPROFEN; IMMUNOGLOBULIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; MACROGOL; MALTOSE; OCTANOIC ACID; PARACETAMOL; POLYOL; SOLVENT; SORBITOL; SUCROSE;

ABDOMINAL PAIN; ACUTE KIDNEY FAILURE; ANAPHYLAXIS; ANGINA PECTORIS; ANXIETY DISORDER; ARTHRALGIA; ASEPTIC MENINGITIS; BACTERIAL INFECTION; BLOOD ANALYSIS; BLOOD VISCOSITY; BONE MARROW TRANSPLANTATION; BRONCHOSPASM; CHILL; CHROMATOGRAPHY; CONSCIOUSNESS DISORDER; CORONARY ARTERY ANEURYSM; CYTOPENIA; DEEP VEIN THROMBOSIS; DIZZINESS; DNA VIRUS; DONOR SELECTION; DOSE RESPONSE; DRUG CONTAMINATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG INDICATION; DRUG INFUSION; DRUG MANUFACTURE; DRUG MEGADOSE; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG TOLERABILITY; ECZEMA; FEVER; FLUSHING; FOLLOW UP; FOOD AND DRUG ADMINISTRATION; GOOD MANUFACTURING PRACTICE; GRAFT INFECTION; HEADACHE; HEALTH STATUS; HEART INFARCTION; HEAT TREATMENT; HEMOLYSIS; HUMAN; HUMORAL IMMUNE DEFICIENCY; HYPOGAMMAGLOBULINEMIA; HYPOTENSION; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNE DEFICIENCY; INSTRUMENT STERILIZATION; IRRITABILITY; LOW BACK PAIN; LUNG EDEMA; LUNG EMBOLISM; LUNG INJURY; MATERIALS HANDLING; MEDICAL DECISION MAKING; MIGRAINE; MUCOCUTANEOUS LYMPH NODE SYNDROME; MYALGIA; NANOFILTRATION; NAUSEA AND VOMITING; NERVE DEGENERATION; OSMOLALITY; PASTEURIZATION; PATIENT SELECTION; PHYSICIAN ATTITUDE; POSTMARKETING SURVEILLANCE; PRECIPITATION; PRION; PRION DISEASE; PRIORITY JOURNAL; QUALITY CONTROL; RASH; RESPIRATORY DISTRESS; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK FACTOR; RNA VIRUS; SEIZURE; SIDE EFFECT; STEVENS JOHNSON SYNDROME; STROKE; SUDDEN DEATH; TACHYCARDIA; THROMBOSIS; URTICARIA; VIRAL CONTAMINATION; VIRUS INACTIVATION; VIRUS INFECTION; VIRUS ISOLATION; WHEEZING;

ANIMALS; BLOOD DONORS; DRUG CONTAMINATION; DRUG INDUSTRY; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; SAFETY; VIRUSES;

EID: 34248181214     PISSN: 15748863     EISSN: None     Source Type: Journal    
DOI: 10.2174/157488607779315480     Document Type: Review

References (77)

1. Orange JS, Hossny EM, Weiler CR, et al. Use of intravenous immunoglobulin in human disease: A review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology. J Allergy Clin Immunol 2005; 117: 525-553.
2. Späth PJ, Kempf C. Challenges and achievements in pathogen safety of intravenous immunoglobulin. In Intravenous Immunoglobulins in the Third Millenium. Parthenon Publishing 2004; 9-20.
3. Yap PL. Viral Safety of IVIG. In Intravenous Immunoglobulin in Clinical Practice. Marcel Dekker 1997; 67-105.
4. Kempf C, Stucki M, Boschetti N. Pathogen inactivation and removal procedures used in the production of intravenous immunoglobulins. Biologicals 2006, in press.
5. Boschetti N, Stucki M, Spath TJ, Kempf C. Virus safety of intravenous immunoglobulin: future challenges. Clin Rev Allergy Immunol 2005; 29: 333-44.
6. Cai K, Gierman TM, Hotta J, et al. Ensuring the Biologic Safety of Plasma-Derived Therapeutic Proteins. Biodrugs 2005; 19: 79-96.
7. Christie JM, Healey CJ, Watson J, et al. Clinical outcome of hypogammaglobulinaemic patients following outbreak of acute hepatitis C: 2 year follow-up. Clin Exp Immunol 1997; 110: 4-8.
8. Echevarria JM, Leon P, Domingo CJ, et al. Laboratory diagnosis and molecular epidemiology of an outbreak of hepatitis C virus infection among recipients of human intravenous immunoglobulin in Spain. Transfusion 1996; 36: 725-730.
9. Carbone J, Sarmiento E, Fernandez-Cruz E. Overwhelming course of HCV disease in patients with hypogammaglobulinemia associated with cellular immunity deficiency. Rev Gastroenterol Peru 2005; 25: 19-22.
10. Quinti I, Pierdominici M, Marziali M, et al. European Surveillance of Immunoglobulin Safety. Results of Initial Survey of 1243 Patients with Primary Immunodeficiencies in 16 Countries. Clin Immunol 2002; 104: 231-236.
11. Razvi S, Schneider L, Jonas MM, Cunningham-Rundles C. Outcome of intravenous immunoglobulin-transmitted hepatitis C virus infection in primary immunodeficiency. Clin Immunol 2001; 101: 284-288.
12. Chapel HM, Christie JM, Peach V, Chapman RW. Five-year follow-up of patients with primary antibody deficiencies following an outbreak of acute hepatitis C. Clin Immunol 2001; 99: 320-324.
13. Plasma Protein Therapeutics Association Overview. Available from www.plasmatherapeutics.org. Accessed 2006 May 10.
14. Rossi F, Legras JF. Viral safety: European and French directives. Ann Med Intern (Paris) 2000; 151: S55-61.
15. European Agency for the Evaluation of Medicinal Products/Commitee for Propietary Medical Products. The introduction of nucleic acid amplification technology (NAT) for the detection of hepatitis C virus RNA in plasma pools (CPMP/BWP/390/97): Addendum to Note for guidance on plasma derived medicinal products (CPM/BWP/269/95). Available from URL: http//www.tga.gov.au/docs/pdf/euguide/Bwp039097en.pdf Accessed 2006 May 10.
16. Alter H, Sanchez-Pescador R, Urdea MS, et al. Evaluation of branched DNA signal amplification for the detection of hepatitis C virus RNA. J Viral Hepat 1995; 2: 121-123.
17. Vrielink H, van der Poel CL, Reesink HW, Zaaijer HL, Lelie PN. Transmission of hepatitis C virus by anti-HCV-negative blood transfusion. Vox Sang 1995; 68: 55-56.
18. Cohn EJ, Strong LE, Hughes WL Jr, et al. Preparation and properties of serum and plasma proteins. IV. A system for the separation into fractions of the proteins and lipoprotein components of biological tissues and fluids. J Am Chem Soc 1946; 68: 459-475.
19. Kistler P, Nitschmann H. Large scale production of human plasma fractions. Vox Sang 1962; 7: 414-424.
20. Lebing W, Remington K, Schreiner C, Paul HI. Properties of a new intravenous immunoglobulin (IVIG-C, 10%) produced by caprylate virus inactivation and column chromatography. Vox Sang 2003; 84: 193-201.
21. Korneyeva M, Hotta J, Lebing W, Rosenthal RS, Franks L, Petteway SR Jr. Enveloped virus inactivation by caprylate: a robust alternative to solvent-detergent treatment in plasma derived intermediates. Biologicals 2002; 30: 153-62.
22. Lundblad L, Seng R, Inactivation of lipid-enveloped viruses in proteins with caprylate. Vox Sang 1991; 60: 75-81.
23. Internal viral clerance reports. Research Triangle Park (NC): Bayer Biological Products, 2003 (Data on file).
24. Uemura Y, Yang YH, Heldebrant CM, Takechi K, Yokoyama K. Inactivation and elimination of viruses during preparation of human intravenous immunoglobulin. Vox Sang 1994; 67: 246-254.
25. Balow M, Berger M, Bonilla FA, et al. Pharmacokinetics and tolerability of a new intravenous immunoglobulin preparation, IVIG-C, 10% (Gamunex, 10%). Vox Sang 2003; 84: 202-210.
26. Trejo SR, Hotta JA, Lebing W. Evaluation of virus and prion reduction in a new intravenous immunoglobulin manufacturing process. Vox Sang 2003; 84: 176-187.
27. Burnouf T, Radosevich M. Affinity chromatography in the industrial purification of plasma proteins for therapeutic use. J Biochem Biophys Methods 2001; 49: 575-586.
28. Chandra S, Groener A, Feldman F. Effectiveness of alternative treatments for reducing potential viral contamination from plasma-derived products. Thromb Res 2002; 105: 391-400.
29. Parkinnen J, Rahola A, von Bonsdorff L, Tolo H, Torma E. A modified caprylic acid method for manufacturing immunoglobulin G from human plasma with high yield and efficient virus clearance. Vox Sang 2006; 90: 97-104.
30. Burnouf T, Radosevich M. Nanofiltration of plasma-derived biopharmaceutical products. Haemophilia 2003; 9: 24-37.
31. Wolf HH, Davies SV, Borte M, et al. Efficacy, tolerability, safety and pharmacokinetics of a nanofiltered intravenous immunoglobulin: studies in patients with immune thrombocytopenic purpura and primary immunodeficiencies. Vox Sang 2003; 84: 45-53.
32. Troccoli NM, McIver J, Losikoff A, Poiley J. Removal of viruses from human intravenous immune globulin by 35 nm nanofiltration. Biologicals 1998; 26: 321-9.
33. Brenner B. Clinical experience with Octagam, a solvent detergent (SD) virus inactivated intravenous gammaglobulin. Clin Exp Rheumatol 1996; 14: S115-9.
34. Biesert L. Virus validation studies of immunoglobulin preparations. Clin Exp Rheumatol 1996; 14: S47-52.
35. Chidwick K, Matejtschuk P, Gascoigne E, Briggs N, More JE, Dash CH. Clinical experience with a new solvent detergent-treated intravenous immunoglobulin free of hypotensive effects. Vox Sang 1999; 77: 204-209.
36. Manucci PM. Viral safety of coagulation factor concentrates. In Brown F editor. Virological safety aspects of plasma derivative. Basel: Karger, 1993: 253-259.
37. Louie RE, Galloway CJ, Dumas ML, Wong MF, Mitra G. Inactivation of hepatitis C virus in low pH intravenous immunoglobulin. Biologicals 1994; 22: 13-19.
38. Blumel J, Schmidt I, Willkommen H, et al. Inactivation of parvovirus B19 during pasteurization of human serum albumin. Transfusion 2002; 42: 101-108.
39. Matamoros N, De Gracia J, Hernandez F, Pons J, Alvarez A, Jimenez V. A prospective controlled crossover trial of a new presentation (10% vs. 51%) of a heat-treated intravenous immunoglobulin. Int Immunophramacol 2005; 5: 619-26.
40. Barrett PN, Meyer H, Wachtel I, et al. Inactivation of hepatitis A virus in plasma products by vapor heating. Transfusion 1997; 37: 215-220.
41. Blumel J, Schmidt I, Effenberger W, et al. Parvovirus B19 transmission by heat-treated clotting factor concentrates. Transfusion 2002; 42: 1473-1481.
42. Dichtelmuller H, Rudnick D, Breuer B, et al. Improvement of virus safety of a S/D-treated factor VIII concentrate by additional dry heat treatment at 100 degrees C. Biologicals 1996; 24: 125-30.
43. Burnouf T, Radosevich M. Reducing the risk of infection from plasma products: specific preventative strategies. Blood Rev 2000; 14: 94-110.
44. Rubinstein AI, Rubinstein DB, Tom W. Terminal 100 degrees C dry-heat treatment of intravenous immunoglobulin preparations to assure sterility. Vox Sang 1995; 68: 255-257.
45. McOmish F, Yap PL, Jordan A, Hart H, Cohen BJ, Simmonds P. Detection of parvovirus B19 in donated blood: a model system for screening by polymerase chain reaction. Clin Microbiol 1993; 31: 323-328.
46. Lee DC, Stenland CJ, Miller JL, et al. A direct relationship between the partitioning of the pathogenic prion protein and transmissible spongiform encephalopathy infectivity during the purification of plasma proteins. Transfusion 2001; 41: 449-455.
47. Van Holten RW, Autenrieth SM. Evaluation of depth filtration to remove prion challenge from an immune globulin preparation. Vox Sang 2003; 85: 20-24.
48. Truchot L, Arnaud T, Bloy C, Perret-Liaudet A. CJD PrP(sc) removal by nanofiltration process: Application to a therapeutic immunoglobulin solution (Lymphoglobuline). Biologicals 2006 (in press).
49. Boschetti N, WyssK, Mischler A, Hostettler T, Kempf C. Stability of minute virus of mice against temperature and sodium hydroxide. Biologicals 2003; 31: 181-185.
50. Pomar SH, Sorensen RU. Immunoglobulin Replacement Therapy in Primary Immunodeficiency Diseases. In: R Rich, TA Fleisher, BD Schwartz, WT Shearer, W Strober, Editors, Clinical Immunology, Principles and Practice, Mosby-Year Book, Inc. St. Louis, Missouri. 1996; 1865-1876.
51. Buckley RH. Primary B-cell diseases. In: R. Behrman, R. Kliegman and A. Arvin, Editors, Textbook of Pediatrics, WB Saunders Company, Philadelphia. 1996; 567-570.
52. Boguniewicz M, Kelly CS, Ballow M, Leung DYM. Intravenous Immune Globulin in Autoimmune and Inflammatory Diseases. In: R Rich, TA Fleisher, BD Schwartz, WT Shearer, W Strober, Editors, Clinical Immunology, Principles and Practice, Mosby-Year Book, Inc. St. Louis, Missouri. 1996; 1891-1903.
53. Kazatchkine MD, Kaveri S. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med 2001; 345: 747-755.
54. Bayari J, Dasgupta S, Misra N, et al. Intravenous immunoglobulin in autoimmune disorders: an insight into the immunoregulatory mechanisms. Int Immunopharmacol 2006; 6: 528-534.
55. Hamrock DJ. Adverse events associated with intravenous immunoglobulin therapy. Int Immunopharmacol 2006; 6: 535-542.
56. Misbah SA, Chapel HM. Adverse Effects of Intravenous Immunoglobulin. Drug Safety 1993; 9: 254-262.
57. Dicato M, Duhem C, Ries F. Nonviral Side Effects of Intravenous Immunoglobulins. In Intravenous Immunoglobulin in Clinical Practice. Marcel Dekker 1997; 67-105.
58. Siegel J. Pharmaceutical considerations and therapeutic issues related to intravenous immune globulin use. Pharmacy Practice News Special Edition 2004; 9: 65-69.
59. Siegel J. Safety considerations in IVIG utilization. Int Immunopharmacol 2006; 6: 523-527.
60. Martin TD. IVIG: Contents, properties, and methods of industrial production-evolving closer to a more physiologic product. Int Immunopharmacol 2006; 6: 517-522.
61. Nielson H. Immunoglobulin preparations for intravenous administration. A review of their biologic activities and comparison of various preparation methods. Allergy 1994; 49: 69-73.
62. Tan E, Hajinazarian M, Bay W, et al. Acute renal failure resulting from intravenous immunoglobulin therapy. Arch Neurol 1993; 50: 137-139.
63. Acute renal failure and intravenous immune globulin: occurs with sucrose-stabilized, but not with D-sorbitol-stabilized, formulation. Ann Pharmacother 2004; 38: 2059-2067.
64. Centers for Disease Control and Prevention (CDC). Renal insufficiency and failure associated with immune globulin intravenous therapy- United States, 1985-1998. MMWR Morb Mortal Wkly Rep 1999; 48: 518-521.
65. Brennan VM, Cochrane S, Fletcher C, et al. Surveillance of adverse reactions in patients self-infusing intravenous immunoglobulin at home. J Clin Immunol 1995; 15: 116-119.
66. Brennan VM, Salome-Bentley NJ, Chapel HM. Prospective audit of adverse reactions occurring in 459 primary antibody-deficient patients receiving intravenous immunoglobulin. Clin Exp Immunol 2003; 133: 247-251.
67. Sherer Y, Levy Y, Langevitz P, Rauova L, Fabrizzi F, Shoenfeld Y. Adverse effects of intravenous immunoglobulin therapy in 56 patients with autoimmune diseases. Pharmacology 2001; 62: 133-137.
68. Ziegner UH, Kobayashi RH, Cunningham-Rundles C, et al. Progressive neurodegeneration in patients with primary immunodeficiency disease on IVIG treatment. Clin Immunol 2002; 102: 19-24.
69. Hammarstrom L, Smith CIE: Anaphylaxis after administration of gamma globulin for hypogammaglobulinaemia. N Engl J Med 1986; 315: 519.
70. Bjorkander J, Hammarstrom L, Smith CIE, Buckley R, Cunningham-Rundles C, Hanson LA. Successful immunoglobulin prophylaxis in patients with antibody deficiency syndromes in the presence of anti-IgA. J Clin Immunol 1987; 7: 8-15.
71. Burks AW, Sampson HA, Buckley RH. Anaphylactic reactions after gamma globulin administration in patients with hypogamma-globulinemia. N Engl J Med 1986; 314: 560-564.
72. Cunningham-Rundles C, Zhou Z, Mankarious S, Courter S. Long-term use of IgA-depleted intravenous immunoglobulin in immunodeficient subjects with anti-IgA antibodies. J Clin Immunol 1993; 13: 272-278.
73. Salama A, Temmesfeld B, Hippenstiel S, Kalus U, Suttorp N, Kiesewetter H. A new strategy for the prevention of IgA anaphylactic transfusion reactions. Transfusion 2004; 44: 509-511.
74. Bonilla FA, Bernstein IL, Khan DA, et al. Practice parameter for the diagnosis and management of primary immunodeficiency. Ann Allergy Asthma Immunol 2005; 94 (suppl): S1-S63.
75. Chapel H. Consensus on diagnosis and management of primary antibody deficiencies. BMJ 1994; 308: 581-585.
76. Sewell WAC, Brennan VM, Donaghy M, Chapel HM. The use of self infused intravenous immunoglobulin home therapy in the treatment of acquired chronic demyelinating neuropathies. J Neurol Neurosurg Psychiatry 1997; 63: 106-109.
77. Orbach H, Katz U, Sherer Y, Sboenfeld Y. Intravenous immunoglobulin adverse effects and safe administration. Clin Rev Allergy Immunol 2005; 29: 173-84.